All In Biotech

Drug Trial Radar · NCT07845604

Precision Depression Adalimumab Trial

An Precision Immunopsychiatric Pharmacological Probe of Adalimumab as an Anti-depressant

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2031

Study completion Sep 2031

Sponsor

Lead sponsor
Daniel MoriarityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Brain & Behavior Research Foundation
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro (escitalopram). The main questions it aims to answer are: 1. Does adalimumab improve the symptoms of some patients with MDD who are already taking an anti-depressant? 2. What characteristics predict for whom adalimumab has anti-depressant properties. Researchers will compare adalimumab to a placebo (a look-alike substance that contains no drug) to see if adalimumab works to improve depressive symptoms as an add-on drug to the anti-depressant Lexapro (escitalopram). For these primary aims the participants will: 1. Visit the clinic once every 2 weeks for a checkups and injection of adalimumab or placebo from the study psychiatrist (Day 1, 15, 29, and 43 for injections) 2. Complete short (\<5 min) daily surveys for the 57 day duration of the study.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • Adalimumab Biosimilars InjectionDrug

    adalimumab biosimilar 100mg/mL

  • PlaceboOther

    placebo injection of same volume as active medication for that visit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in individual somatic, affective, and motivational depressive symptoms, as measured by the Quick Inventory of Depressive Symptomatology (QIDS)Time frame: From start of trial to the end of study (Day 57)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.